Medicine
Lytenava 1.25 mg injection
Lytenava 1.25 mg injection is a prescription medicine containing Bevacizumab for intravitreal use, marketed by Outlook Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store LYTENAVA refrigerated at 2º C to 8º C (36º F to 46º F) in the original…
Key facts
- Active ingredient (INN)
- Bevacizumab
- Brand
- Lytenava
- Strength
- 1.25 mg
- Dosage form
- Injection
- Route
- Intravitreal
- Packs
- 1 vial
- Marketing authorisation holder
- Outlook Therapeutics
- Manufacturer
- Outlook Therapeutics
- Origin register
- US FDA, United States
- Storage
- Store LYTENAVA refrigerated at 2º C to 8º C (36º F to 46º F) in the original carton until use to protect from light. DO NOT FREEZE. Prior to use, the unopened glass vial of LYTENAVA may be kept at room temperature, 20º C to 25º C (68º F to 77º F), for up to 12 hours.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01FG01 Bevacizumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 16 July 2026
- Identifiers
- RxCUI 2749110, 2749117DailyMed set ID 7f9a3014-b3d4-4943-a83a-92a77d8f947cNDC 82491-025Application BLA761320
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, glass in 1 carton / 1 injection in 1 vial, glass | 82491-025-10 | Outlook Therapeutics | 16 July 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Bevacizumab
Clinical summary
Bevacizumab is a vascular endothelial growth factor inhibitor indicated for the treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment, among other approved uses. MedsAcross supplies Bevacizumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about BevacizumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Avastin prescribing information (Genentech) · U.S. National Library of Medicine, DailyMed
- Avastin: European public assessment report (EPAR) · European Medicines Agency
- Lytenava: European public assessment report (EPAR) · European Medicines Agency
Need Lytenava 1.25 mg injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.